- Home
- ROIV vs ENSG Comparison
ROIV vs ENSG Comparison
Compare ROIV & ENSG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ROIV | ENSG |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.1B | 10.5B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | ROIV | ENSG |
|---|---|---|
| Price | $22.56 | $181.05 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 5 |
| Target Price | $24.31 | ★ $196.40 |
| AVG Volume (30 Days) | ★ 8.2M | 356.5K |
| Earning Date | 02-09-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 0.14% |
| EPS Growth | N/A | ★ 35.03 |
| EPS | N/A | ★ 5.59 |
| Revenue | $20,329,000.00 | ★ $4,829,467,000.00 |
| Revenue This Year | N/A | $21.00 |
| Revenue Next Year | $376.94 | $12.30 |
| P/E Ratio | ★ N/A | $32.45 |
| Revenue Growth | N/A | ★ 17.55 |
| 52 Week Low | $8.73 | $118.73 |
| 52 Week High | $23.47 | $194.00 |
Technical Indicators
Market Signals| Indicator | ROIV | ENSG |
|---|---|---|
| Relative Strength Index (RSI) | 61.61 | 56.04 |
| Support Level | $21.60 | $172.95 |
| Resistance Level | $23.47 | $180.00 |
| Average True Range (ATR) | 0.88 | 3.97 |
| MACD | 0.06 | 0.21 |
| Stochastic Oscillator | 69.09 | 68.15 |
Price Performance
Historical ComparisonAbout ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About ENSG The Ensign Group Inc.
Ensign Group Inc provides post-acute healthcare services in the United States. Its regional subsidiaries oversee skilled nursing, assisted living, home health and hospice, mobile ancillary, and urgent care operations. Medicare and Medicaid programs contribute majority of revenue received for Ensign's services. The firm operates through two segments, Skilled services, and Standard Bearer. The skilled services segment includes the operation of skilled nursing facilities and rehabilitation therapy services. The Standard Bearer segment comprises of properties owned by the company through its captive REIT and leased to skilled nursing and assisted living operations. The majority of the revenue is generated from the skilled services segment.